SCHEMBL3789425

SCHEMBL3789425

N#Cc1ccc2c(c1)nc(Cl)c1cccn12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.61
ALDH1A1 P00352 3/20 0.61
GLA P06280 1/20 0.61
GAA P10253 1/20 0.61
PTPN1 P18031 3/20 0.42
CSNK2A2 P19784 2/20 0.42
CSNK2B P67870 2/20 0.42
CSNK2A1 P68400 2/20 0.42
RAD51 Q06609 3/20 0.40
HPGD P15428 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
CYP11B2 P19099 1/20 0.38
PTPN2 P17706 1/20 0.37
MAPT P10636 2/20 0.37
HTR3E A5X5Y0 2/20 0.37
HTR3B O95264 2/20 0.37
HTR3A P46098 2/20 0.37
HTR3D Q70Z44 2/20 0.37
HTR3C Q8WXA8 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7401133 0.80 PTPN1 (0.54) KDM4EALDH1A1GLAGAAPTPN1
SCHEMBL124061 0.77 KDM4E (0.51) KDM4EALDH1A1GLAGAAHPGD
SCHEMBL1079670 0.77 RAD51 (0.58) KDM4EALDH1A1PTPN1RAD51HPGD
SCHEMBL7400768 0.77 HTR3E (0.57) KDM4EALDH1A1PTPN1RAD51HPGD
SCHEMBL13082235 0.77 RAD51 (0.51) KDM4EALDH1A1GLAGAAPTPN1
SCHEMBL13056851 0.76 KDM4E (0.56) KDM4EALDH1A1GLAGAACSNK2A2
SCHEMBL8569855 0.76 PTPN1 (0.61) KDM4EALDH1A1GLAGAAPTPN1
SCHEMBL7400933 0.73 RAD51 (0.61) KDM4EALDH1A1PTPN1RAD51HPGD
SCHEMBL29893316 0.73 RAD51 (0.52) KDM4EALDH1A1GLAGAARAD51
SCHEMBL13056861 0.73 ALDH1A1 (0.56) KDM4EALDH1A1GLAGAAPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298302-A1 NOVEL PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2010-11-25 US disclosed
US-20100298302-A1 NOVEL PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2010-11-25 US disclosed
US-20100298302-A1 NOVEL PROTEIN KINASE MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2010-11-25 US disclosed
WO-2010135571-A1 NOVEL PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2010-11-25 WO disclosed
WO-2010135571-A1 NOVEL PROTEIN KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298302-A1 NOVEL PROTEIN KINASE MODULATORS PIM2, PIM1, PIM3 KDM4E 1746/4885ALDH1A1 4648/4885GLA 4598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.